Tests a laser eye treatment for pseudoexfoliation glaucoma
Tests direct laser treatment of the eye's drainage channels in people with pseudoexfoliation glaucoma.
Plain-language title generated from the registry record
Registry title: The Safety and Efficacy of Direct SLT in Pseudoexfoliation Glaucoma
Key facts
- Where
- Alexandria, Fargo, and Omaha, United StatesSee the 3 sites
Where in United States
- Vance Thompson VisionAlexandria, United StatesNo longer taking part
- Vance Thompson VisionFargo, United StatesNo longer taking part
- Vance Thompson VisionOmaha, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vance Thompson Vision
- Trial code
- NCT07401290
- Record updated
- 10 February 2026
- Original description
Prospective, multi-center, single arm, interventional study evaluating DSLT in patients with pseudoexfoliative glaucoma.Read full original descriptionShow less
The Safety and Efficacy of Direct SLT in Pseudoexfoliation Glaucoma
Prospective, multi-center, single arm, interventional study evaluating DSLT in patients with pseudoexfoliative glaucoma.
Inclusion: Adult patients diagnosed with pseudoexfoliation glaucoma (PXFG), with optic neuropathy consistent with glaucomatous damage of any severity; Open iridocorneal angle by gonioscopy, defined as a Shafer Grade II or greater; Treatment naive, or washed out IOP ranging from ≥18-35 mmHg; Able to complete medication washout safely and all follow-up visits; Participants must have a best correct visual acuity of 20/40 or better in the study eye(s), be able to undertake a reliable Humphrey visual field (HVF) (defined as fixation losses, false positives and false negatives less than 33%), and must have field loss no worse than -20 dB in treatment eye.
Exclusion: Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye; Any prior refractive surgery; A history of any significant cataract required during study duration or cataract surgery in the last 6 months; History of ocular inflammation and infection; Patients who are pregnant or have any clinically relevant systemic disease that may prevent them from reliably completing follow-up visits; Prior laser trabeculoplasty (ALT/SLT); Any contraindication to SLT or unable to have DSLT; Angle closure glaucoma or any other types of glaucoma other than PXFG; H/o LPI within last 6 months; Vulnerable populations that cannot provide proper informed consent will not be enrolled, such as children, prisoners, handicapped, or mentally disabled persons, or economically or educationally disadvantaged persons.